| Drug Name |
Edaravone |
| Drug ID |
BADD_D02508 |
| Description |
Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development. |
| Indications and Usage |
Indicated for improving neurological symptoms and damage from acute ischemic stroke and delaying disease progression of ALS. |
| Marketing Status |
Not Available |
| ATC Code |
N07XX14 |
| DrugBank ID |
DB12243
|
| KEGG ID |
D01552
|
| MeSH ID |
D000077553
|
| PubChem ID |
4021
|
| TTD Drug ID |
D06DLI
|
| NDC Product Code |
53296-0120; 73435-008; 64552-4098; 70510-2191; 53069-1070; 69037-0060; 70510-2171; 14501-0100; 71796-017; 16436-0120 |
| Synonyms |
Edaravone | Norantipyrine | Norphenazone | Edarabone | 1-Phenyl-3-methyl-5-pyrazolone | 1 Phenyl 3 methyl 5 pyrazolone | 3-Methyl-1-phenyl-2-pyrazolin-5-one | 3 Methyl 1 phenyl 2 pyrazolin 5 one | MCI 186 | MCI-186 | MCI186 | Radicava | Phenylmethylpyrazolone |
